

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5160
("Mediclinic", the "Company", or the "Group")

5 April 2023

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B8HX8Z88

Issuer Name

MEDICLINIC INTERNATIONAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

The Goldman Sachs Group, Inc.

City of registered office (if applicable)

Wilmington, Delaware

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name	City of registered office	Country of registered office
Goldman Sachs International	London	United Kingdom

5. Date on which the threshold was crossed or reached

31-Mar-2023

6. Date on which Issuer notified

04-Apr-2023

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached	1.074447	3.974818	5.049265	37225409
Position of previous notification (if applicable)	1.086378	4.001370	5.087748	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88		7921295		1.074447
Sub Total 8.A	7921295		1.074447%	

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Securities Lending	Open		10182014	1.381092
Swap	15-June-2023		8997334	1.220401
Sub Total 8.B1			19179348	2.601493%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Swap	23-May-2023		Cash	8680444	1.177418
Swap	17-Aug-2026		Cash	384361	0.052135
Swap	08-Mar-2033		Cash	259311	0.035173
Swap	30-Mar-2033		Cash	185482	0.025159
Swap	17-Aug-2026		Cash	132285	0.017943
Swap	05-Jan-2033		Cash	106211	0.014406

Swap	17-Aug-2026		Cash	92303	0.012520
Swap	15-Jul-2031		Cash	89654	0.012161
Swap	17-Aug-2026		Cash	45724	0.006202
Swap	17-Aug-2026		Cash	42134	0.005715
Swap	17-Aug-2026		Cash	36389	0.004936
Swap	17-Aug-2026		Cash	19183	0.002602
Swap	17-Aug-2026		Cash	12608	0.001710
Swap	17-Aug-2026		Cash	12160	0.001649
Swap	20-Oct-2032		Cash	8893	0.001206
Swap	17-Aug-2026		Cash	5939	0.000806
Swap	17-Aug-2026		Cash	3974	0.000539
Swap	17-Aug-2026		Cash	3606	0.000489
Swap	28-Jul-2032		Cash	1915	0.000260
Swap	11-Oct-2023		Cash	1381	0.000187
Swap	17-Aug-2026		Cash	756	0.000102
Swap	30-May-2023		Cash	37	0.000005
Swap	09-May-2023		Cash	16	0.000002
Sub Total 8.B2				10124766	1.373325%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Goldman Sachs Group, Inc. (Chain 1)				
The Goldman Sachs Group,	Goldman Sachs (UK) L.L.C.	1.063875	3.974616	5.038491%

Inc. (Chain 1)				
The Goldman Sachs Group, Inc. (Chain 1)	Goldman Sachs Group UK Limited	1.063875	3.974616	5.038491%
The Goldman Sachs Group, Inc. (Chain 1)	Goldman Sachs International	1.063875	3.974616	5.038491%
The Goldman Sachs Group, Inc. (Chain 2)				
The Goldman Sachs Group, Inc. (Chain 2)	GSAM Holdings LLC			
The Goldman Sachs Group, Inc. (Chain 2)	Goldman Sachs Asset Management, L.P.			
The Goldman Sachs Group, Inc. (Chain 3)				
The Goldman Sachs Group, Inc. (Chain 3)	Goldman Sachs Bank USA			
The Goldman Sachs Group, Inc. (Chain 3)	Goldman Sachs Bank Europe SE			
The Goldman Sachs Group, Inc. (Chain 4)				
The Goldman Sachs Group, Inc. (Chain 4)	Goldman Sachs & Co. LLC			

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

Please note, the total amount of voting rights have been rounded to 6 decimal places therefore there is a possibility of a rounding error.

General email contact:

gs-regops-emea-position-enquiries@gs.com

12. Date of Completion

04-Apr-2023

13. Place Of Completion

Warsaw

ABOUT MEDICLINIC INTERNATIONAL PLC

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 December 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and five day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 750 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

CONTACT INFORMATION

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

+44 (0)20 3786 8181

ir@mediclinic.com

Media queries

FTI Consulting

Ben Atwell/Ciara Martin – UK

+44 (0)20 3727 1000

Sherryn Schooling – South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd